Race for Next-Gen Weight Loss Pills Intensifies

Pharmaceutical companies are developing oral GLP-1 drugs as alternatives to injections. Two teams published Phase II trial data this month on candidates aleniglipron and elecoglipron, showing weight loss comparable to existing options. Eli Lilly's oral pill Foundayo (ofolifeigron) was approved in April, while Astrazeneca advances elecoglipron.